$KRRO News
Last published 5d ago
- 5d agoKRROKorro to Present at the 2026 Jefferies Global Healthcare Conference in LondonGlobeNewswireCAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging a novel...
- 5d agoKRROKorro to Present at the 2026 Jefferies Global Healthcare Conference in LondonGlobeNewswireCAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to
- 6d agoKRROKorro Bio, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 1.02 Item 2.02 Item 9.01
- 6d agoKRROKorro Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireStarted dosing healthy volunteers with KRRO-121 in the Phase 1/2 clinical trial (ANCHOR) Expect to dose participants with Urea Cycle Disorders (UCDs) in the first half of 2027Anticipate reporting interim data in the
- 2w agoKRROKorro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin DeficiencyGlobeNewswireRepeat dose mouse studies achieved >95% SERPINA1 mRNA editing, sustained restoration of circulating functional M-AAT and increased total AAT by ~6-fold KRRO-111 reduced pathogenic hepatic Z-AAT by up to 95%,
- 3w agoKRROKorro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to
- 2mo agoKRROKorro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new
- 2mo agoKRROKorro to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new
- 2mo agoKRROKorro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new
- 3mo agoKRROKorro Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireKRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in second half of 2026 Received Orphan Drug Designation from the European
- 4mo agoKRROKorro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., July 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class
- 5mo agoKRROKorro to Present at the 2026 Jefferies Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new
- 5mo agoKRROKorro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)GlobeNewswirePotential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungsDemonstrated >90% editing of SERPINA1 transcript
- 6mo agoKRROKorro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new
- 6mo agoKRROKorro Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireHosted virtual Analyst Day showcasing lead program KRRO-121's potential to be a first-in-class transformational treatment for hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy (HE);
- 6mo agoKRROKorro to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new
- 6mo agoKRROKorro Announces Oral and Poster Presentations at Upcoming Scientific ConferencesGlobeNewswireAmerican Society of Gene and Cell Therapy 29th Annual Meeting (ASGCT) TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference3rd International Conference on Ureagenesis Defects and Allied ConditionsEuropean
- 7mo agoKRROKorro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent
- 8mo agoKRROKorro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswireNominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathyAdvanced GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin
- 8mo agoKRROKorro Announces Oversubscribed $85 Million Private PlacementGlobeNewswireFinancing led by new investor Venrock Healthcare Capital Partners, with participation from new and existing investors Proceeds support the achievement of value inflection points for multiple RNA editing programs
- 8mo agoKRROKorro to Present at the TD Cowen 46th Annual Health Care ConferenceGlobeNewswireCAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent
- 9mo agoKRROKorro Bio Analyst Day - KORRO BIO INCEarnings Call TranscriptsGreetings. Welcome to CoralBio's Analyst Day discussing KRRO121, a potential first-in-class treatment for ammonia control. At this time, all participants are in a listen-only mode. A question-and-answer session will foll
- 9mo agoKRROKorro to Host Virtual Analyst Day on January 27, 2026GlobeNewswire- Program to feature presentations from the company management about KRRO-121 for the potential treatment of hyperammonemia, a leading clinical hepatologist about ammonia-driven diseases, and a caregiver sharing
- 10mo agoKRROKorro to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan
- 12mo agoKRROKorro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline ProgramsGlobeNewswireCAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- —KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency (AATD) patients —KRRO-110 did not reach projected levels of functional protein following a
- 1y agoKRROKorro to Participate in Upcoming Investor and Scientific ConferencesGlobeNewswireCAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences for
- 1y agoKRROKorro Reports Second Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire— Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 on track for the second half of 2025 — Completed dosing of over 80% of planned REWRITE healthy volunteers across multiple single ascending dose
- 1y agoKRROKorro Receives European Medicines Agency Orphan Drug Designation for KRRO-110GlobeNewswireCAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both
- 1y agoKRROKorro to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) today announced that members of management will participate in the following upcoming investor conferences: 2025 RBC Capital
- 1y agoKRROKorro Reports First Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire—Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) on track for the second half of 2025 —Streamlining operations and focusing on delivering potential value
- 1y agoKRROKorro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific OfficerGlobeNewswireCAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for
- 1y agoKRROKorro Reports Full Year 2024 Financial Results and Provides Business UpdatesGlobeNewswire—Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim readout expected in the second half of 2025 —U.S. Food and Drug Administration
- 1y agoKRROKRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin DeficiencyGlobeNewswireCAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for
- 1y agoKRROKorro to Present at the TD Cowen 45th Annual Health Care ConferenceGlobeNewswireCAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both
- 1y agoKRROKorro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline UpdateGlobeNewswireKRRO-110 is the first product candidate from Korro's proprietary RNA editing OPERATM platformInterim readout from REWRITE expected in the second half of 2025 Korro to advance additional pipeline programs towards clinical
- 1y agoKRROKorro to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both
- 1y agoCAMPKRROCAMP4 Appoints John Maraganore and Rachel Meyers as Strategic AdvisorsGlobeNewswireCAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to
- 1y agoKRROKorro to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both
- 1y agoKRROKorro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin DeficiencyGlobeNewswire-REWRITE study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of KRRO-110 -First participant dosing anticipated in the first quarter of 2025
- 1y agoKRROKorro to Present at the Jefferies London Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly
- 1y agoKRROKorro Reports Third Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire- Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) - Formed Clinical Advisory Board (CAB) of leading lung and liver experts and
- 2y agoKRROKorro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory BoardGlobeNewswire-Regulatory filing of Phase 1/2 clinical study for Alpha-1 Antitrypsin Deficiency (AATD) submitted to Australian Bellberry Human Research Ethics Committee (HREC) -Clinical Advisory Board of lung and liver experts formed
- 2y agoKRROKorro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics SocietyGlobeNewswireCAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and
- 2y agoKRROKorro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic CandidatesGlobeNewswirePartnership leverages Korro's proprietary OPERATM platform to enable its oligonucleotide-directed RNA edits into two undisclosed targets; initially for cardiometabolic diseases Total deal value of up to $530 million in
- 2y agoKRROKorro to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and
- 2y agoKRROMRKRPLRXKorro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and
- 2y agoKRROKorro to Participate in Upcoming September Investor and Scientific ConferencesGlobeNewswireCAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly
- 2y agoKRROKorro Reports Second Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire—Regulatory filing of first-in-human (FIH) trial of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) anticipated in the second half of 2024 —Preclinical data presented at the American Thoracic Society
- 2y agoKRROKorro Joins the Russell 2000®, Russell 3000®, and Russell Microcap® IndexesGlobeNewswireCAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly
- 2y agoKRROKorro to Participate in Upcoming June Investor and Scientific ConferencesGlobeNewswireCAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences: